allergen

Rosin is a natural product,may have therapeutic potential for the treatment of inflammation

Allergen Gal d 4 (46-61), chicken, is a peptide derived from hen egg white lysozyme.

ZD-2138 is a potent and selective specific inhibitor of 5-lipoxygenase (5-LOX) that inhibits allergen-induced pulmonary bronchoconstriction and reduces neurally-induced fast-acting kallikrein-ergic constriction of isolated airways in guinea pigs.ZD-2138 can be used for the treatment of asthma disease.

S-Y048 is an Oxoeicosanoid (OXE) receptor antagonist that inhibits allergen-induced eosinophil infiltration into the skin of experimentally sensitized rhesus monkeys to house dust mites and inhibits lung inflammation caused by aerosolized allergen challenge. S-Y048 can be used to study asthma and other eosinophilic diseases.

Ethylparaben (Ethyl parahydroxybenzoate) is a Standardized Chemical Allergen. The physiologic effect of ethylparaben is by means of Increased Histamine Release, and Cell-mediated Immunity.

Chlorquinaldol (5,7-Dichloro-8-hydroxy-2-methylquinoline) is a Standardized Chemical Allergen. The physiologic effect of chlorquinaldol is by means of Increased Histamine Release, and Cell-mediated Immunity.

Butylparaben (Butyl 4-hydroxybenzoate) is a standardized chemical allergen, increasing histamine release, and cell-mediated immunity.

Eugenol (Allylguaiacol) is a Standardized Chemical Allergen. The physiologic effect of eugenol is by means of Increased Histamine Release and Cell-mediated Immunity.

Tulipalin A (α-methylene-γ-butyrolactone) (2-Methylenebutyrolactone) which has some phytotoxicity is a natural compound extracted from Tulipa gesneriana.

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

AZD5423 is an inhaled, potent, selective, and non-steroidal modulator of the glucocorticoid receptor (GR) that effectively reduces allergen-induced responses in individuals with mild allergic asthma.

1,4-Phenylenediamine-15N2 is a 15N2-labeled version of 1,4-phenylenediamine. This compound serves as a molecular building block in the synthesis of composite materials. Additionally, 1,4-phenylenediamine is an ingredient in hair dyes and is known as a potential skin allergen.

ADAM17-IN-1 is a selective ADAM17 inhibitor. It functions by reducing dendritic cell (DC) metabolic activity through ADAM17 inhibition, thereby impairing DC antigen presentation, suppressing allergen-specific Th2 cell polarization, and decreasing the secretion of Th2 cytokines (IL-4, IL-5, IL-13). In mouse models of house dust mite (HDM)-induced type 2/eosinophilic airway inflammation, ADAM17-IN-1 demonstrates protective effects. This compound can be utilized in research on type 2 hyperreactive allergic asthma.

PPARγ antagonist

(±)12(13)-DiHOME is the diol form of (±)12(13)-EpOME , a cytochrome P450-derived epoxide of linoleic acid also known as isoleukotoxin. [1] It is formed from 12(13)-EpOME by soluble epoxide hydrolase (sEH) in neutrophils. [2] 12(13)-DiHOME is toxic to Sf21 cells expressing sEH and to lacZ-expressing control cells, unlike isoleukotoxin, which is only toxic to cells containing sEH.[1] [2] Levels of 12(13)-DiHOME are increased in rat spinal cord following burn injury, and it enhances cold tolerance, increases fatty acid uptake into brown adipocytes, and decreases serum triglyceride levels in mice. Levels are also elevated in bronchoalveolar lavage fluid (BALF) in humans following exposure to biodiesel exhaust and in exhaled breath condensate in patients with allergic asthma following allergen exposure.[5] [6] Plasma levels of 12(13)-DiHOME are increased immediately following moderate-intensity exercise in mice and humans, an effect that can be prevented by brown adipose tissue removal in the mouse.[7]

Olcorolimus inhibits single allergen-induced allergic inflammation such as eosinophilic and lymphocytic infiltration and mRNA expression for interleukin (IL)-4 and IL-5

Talizumab (TNX 901) is a humanized IgG1 monoclonal antibody that specifically targets circulating immunoglobulin E (IgE). it binds to free IgE not already bound by the high-affinity IgE receptors (FcεRI) present on mast cells and basophils, which leads to the marked downregulation of these receptors and additionally inhibits allergen-specific T-cell activation by interfering with antigen processing and presentation activities.

Palmitoyl tripeptide-8, a bioactive peptide known for its anti-allergen properties, is reported to be used as a cosmetic ingredient [1].

Mevlonerbart, an IgG4κ antibody, specifically targets human Felcat allergen 1, an allergen protein.

Freneslerbart, an IgG4κ antibody, specifically targets Felcat allergen 1, an allergenic protein [1].

Bremzalerbart is a human IgG4 antibody targeting BETVIA, the primary allergen Bet v 1-A [1] in birch pollen.

Atisnolerbart, a human IgG4 antibody, specifically targets BETVIA, which is identified as the major birch pollen allergen, Bet v 1-A.

3-Bromotyrosine, a product of protein oxidation, is generated after eosinophil activation during allergic responses. It serves as a biomarker for eosinophil peroxidase-induced protein oxidation both in vitro and in vivo. Beyond its association with eosinophils, 3-bromotyrosine levels are significantly elevated in peritoneal exudate from K. pneumoniae-infected mice, indicating a fivefold increase compared to uninfected controls, which implies that neutrophils may release increased levels of oxidized products during inflammation. Furthermore, in humans, allergen-challenged lung samples from patients with allergen-induced asthma show a tenfold increase in 3-bromotyrosine, highlighting its potential as a marker for oxidative stress in allergic conditions.

HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].